Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ardelyx, Inc. (NASDAQ: AR
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
11:45am, Sunday, 01'st Aug 2021
New York, New York--(Newsfile Corp. - August 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are ad
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” o
ARDX ALERT: Investors with Substantial Losses Have Opportunity to Lead the Ardelyx Inc. Class Action Lawsuit
08:41pm, Friday, 30'th Jul 2021
SAN DIEGO--(BUSINESS WIRE)-- #ARDXstock--The suit alleges defendants issued false statements concerning Ardelyx business and prospects, resulting in its stock trading at inflated prices.
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Ardelyx Inc. (NASDAQ: ARDX)
03:38pm, Friday, 30'th Jul 2021
NEW YORK--(BUSINESS WIRE)-- #ARDX--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Ardelyx Inc. (NASDAQ: ARDX)
Ardelyx's Tenapanor Application For Chronic Kidney Disease Receives FDA Response Letter
07:42am, Friday, 30'th Jul 2021
The FDA has issued a Complete Response Letter (CRL) to Ardelyx Inc's (NASDAQ: ARDX) marketing application seeking approval for tenapanor to control serum phosphorus in adult patients with chronic
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
08:29pm, Wednesday, 28'th Jul 2021
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to c
REMINDER: Scott+Scott Attorneys at Law LLP Continues its Investigation into Ardelyx Inc. (ARDX)
04:21pm, Wednesday, 28'th Jul 2021
NEW YORK--(BUSINESS WIRE)-- #ARDX--REMINDER: Scott+Scott Attorneys at Law LLP Continues its Investigation into Ardelyx Inc. (ARDX)
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ardelyx, Inc.
06:21pm, Wednesday, 21'st Jul 2021
NEW YORK--(BUSINESS WIRE)---- $ARDX--The law firm of Kirby McInerney LLP is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). The investigation
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA
11:37am, Wednesday, 21'st Jul 2021
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
Ademi LLP Investigates Claims of Securities Fraud against Ardelyx, Inc.
03:17am, Wednesday, 21'st Jul 2021
MILWAUKEE, July 21, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Ardelyx (Nasdaq: ARDX). The investigation results from inaccurate statements Ardelyx may h
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
01:15am, Wednesday, 21'st Jul 2021
NEW YORK, July 21, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to
Scott+Scott Attorneys at Law LLP Announces Investigation into Ardelyx Inc. (ARDX)
05:56pm, Tuesday, 20'th Jul 2021
NEW YORK--(BUSINESS WIRE)-- #ARDX--Scott+Scott Attorneys at Law LLP Announces Investigation into Ardelyx Inc. (ARDX)
Why Ardelyx Shares Tanked Today
03:31pm, Tuesday, 20'th Jul 2021
Ardelyx (NASDAQ: ARDX) shares are trading lower after the company received an FDA letter regarding its NDA for tenapanor indicating deficiencies that preclude discussion of labeling and post-marketin
